文献速递免疫规划妇幼与学校卫生

孕妇接种四价灭活流感疫苗的免疫原性及脐带血中接种后抗体水平

Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
PubMed 文献 · Vaccine · 2025-04-08

2021/2022和2022/2023季节开展前瞻性单组临床研究,62名孕14–37周孕妇(含59对母婴)接种四价灭活流感疫苗(IIV4),以EMA标准评估免疫原性。接种后血清保护率71%–94%,所有疫苗株抗体滴度显著升高,2nd与3rd孕期接种组间血清保护率、血清转换率及胎盘抗体转运无显著差异。

要点

  • 接种后血清保护率为71%–94%,所有疫苗株抗体滴度显著升高。
  • 2nd与3rd孕期接种的血清保护率、血清转换率及胎盘抗体转运无显著差异。
  • 新生儿对A/H1N1/pdm09、A/H3N2、B/V、B/Y抗原血清保护率分别为97%、95%、59%、85%。

核心结论

  • IIV4在孕妇中诱导强免疫应答,新生儿获得高血清保护率。
  • 儿童免疫保护不因孕期接种的孕期不同而不同。
  • IIV4在孕妇中耐受性良好。

研究设计与样本

  • 前瞻性单组临床研究,于2021/2022和2022/2023季节开展。
  • 62名孕14–37周孕妇(含59对母婴)接种IIV4。
  • 采用EMA标准评估体液免疫应答。

主要发现

  • 所有IIV4疫苗株的基线血清保护与既往接种显著相关(p < .5)。
  • 接种后血清保护率范围为71%–94%。
  • 所有疫苗株抗体滴度均显著升高(p < .0000)。
  • 2nd与3rd孕期接种组间血清保护率、血清转换率及胎盘抗体转运无显著差异。
  • 新生儿对A/H1N1/pdm09、A/H3N2、B/V、B/Y抗原的血清保护率分别为97%、95%、59%、85%。

关键数值与推荐

  • 研究中所用全部IIV4疫苗株至少满足3项EMA/CPMP免疫原性标准中的1项,因此可认为具有免疫原性。
  • 超过43%的参与者报告了 solicited 注射部位反应。
  • 无参与者报告严重或非 solicited 不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infants and pregnant women are particularly vulnerable to severe illness and complications of influenza. It is necessary to increase knowledge about the safety and effectiveness of influenza vaccination during pregnancy to improve awareness among patients and healthcare professionals and increase to increase vaccination coverage. METHODS: A prospective, single-group clinical study was performed in the 2021/2022 and 2022/2023 seasons. The aim of the study was to assess the immunogenicity and tolerance of quadrivalent influenza vaccine (IIV4) in pregnant women, to evaluate transplacental antibody (AB) transfer after IIV4 administration, and to estimate optimal gestational age for vaccination. A group of 62 pregnant women between 14 and 37 weeks of gestation, including 59 mother-child pairs, underwent vaccination with IIV4. The humoral immune response was assessed using the EMA criteria. RESULTS: Baseline seroprotection for all IIV4 strains was significantly correlated with previous vaccinations (p < .5). The postvaccination seroprotection ranged between 71 % and 94 %. A significant increase in AB titers was observed for all vaccine strains (p < .0000). No significant differences were observed in seroprotection and seroconversion rates or transplacental AB transfer between women vaccinated in the 2nd vs 3rd trimester of pregnancy. All IIV4 strains used in the study met at least 1 of the 3 EMA/CPMP immunogenicity criteria and may thus be considered immunogenic. Seroprotection for A/H1N1/pdm09, A/H3N2, B/lineage Victoria (B/V), and B/lineage Yamagata (B/Y) antigens was achieved by 97 %, 95 %, 59 %, and 85 % of neonates, respectively. Over 43 % of participants reported solicited injection site reactions. None of the participants reported severe or unsolicited adverse events. CONCLUSIONS: IIV4 induced a strong immune response in pregnant women and a high rate of seroprotection in neonates. Immune protection in children did not differ according to the trimester of vaccination in pregnancy. IIV4 was well tolerated by pregnant women.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zasztowt-Sternicka M, Jagielska A, Rząd M, et al. Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood. Vaccine. 2025. PMID: 40203592. doi:10.1016/j.vaccine.2025.127047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。